OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PMCK57

PMCK Bhd

Healthcare Facilities & ServicesVerified

PMCK Bhd has a strong capital structure with a debt-to-equity ratio of 0.24, indicating a relatively low level of leverage. The company's liquidity is assessed as medium, and its current ratio of 2.84 suggests it has sufficient short-term assets to cover its short-term liabilities. However, the company has a negative net cash position after subtracting total debt, which could pose a liquidity risk. In terms of profitability, PMCK Bhd has a return on equity of 12.53% and a return on assets of 9.24%, which are key metrics for evaluating the company's performance. These figures suggest that the company is generating a reasonable return on its equity and assets. The company's operating income of MYR 16,101,000 and net income of MYR 11,334,000 indicate a healthy profit margin. PMCK Bhd's revenue is primarily derived from its three main segments: Specialist consultant services, Healthcare support services, and Other services. The company's geographic exposure is not specified, but its operations are centered around its private hospital, Putra Medical Centre. The company has over 17 medical specializations and a team of resident and visiting specialist consultants, which contributes to its revenue concentration in the healthcare sector. The company's growth trajectory is not explicitly detailed, but its revenue of MYR 93,273,000 and operating cash flow of MYR 14,903,000 suggest a stable financial position. The company's capital expenditure of MYR -15,883,000 indicates that it is investing in its operations, which could support future growth. However, the company's free cash flow of MYR 200,000 is relatively low, which may limit its ability to reinvest in the business. The risk assessment for PMCK Bhd indicates a medium liquidity risk and a low dilution risk. The company's key flags include a negative net cash position after subtracting total debt, which could affect its liquidity. The company's dilution risk is low, suggesting that there is little immediate threat to shareholder value from new share issuances. Recent events related to PMCK Bhd are not specified in the provided data. However, the company's financial performance and risk profile suggest that it is a stable player in the healthcare sector. The company's operations and financial metrics indicate that it is well-positioned to continue providing its services and maintaining its market position.

30-day price · PMCK+0.00 (+0.0%)
Low$0.20High$0.23Close$0.20As of17 May, 00:00 UTC
Profile
CompanyPMCK Bhd
TickerPMCK.KL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. PMCK Bhd is an investment holding company that operates a private hospital, Putra Medical Centre, and provides specialist consultant services, healthcare support services, and other services including general dental and polyclinic services.

Classification. PMCK Bhd is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

PMCK Bhd has a strong capital structure with a debt-to-equity ratio of 0.24, indicating a relatively low level of leverage. The company's liquidity is assessed as medium, and its current ratio of 2.84 suggests it has sufficient short-term assets to cover its short-term liabilities. However, the company has a negative net cash position after subtracting total debt, which could pose a liquidity risk. In terms of profitability, PMCK Bhd has a return on equity of 12.53% and a return on assets of 9.24%, which are key metrics for evaluating the company's performance. These figures suggest that the company is generating a reasonable return on its equity and assets. The company's operating income of MYR 16,101,000 and net income of MYR 11,334,000 indicate a healthy profit margin. PMCK Bhd's revenue is primarily derived from its three main segments: Specialist consultant services, Healthcare support services, and Other services. The company's geographic exposure is not specified, but its operations are centered around its private hospital, Putra Medical Centre. The company has over 17 medical specializations and a team of resident and visiting specialist consultants, which contributes to its revenue concentration in the healthcare sector. The company's growth trajectory is not explicitly detailed, but its revenue of MYR 93,273,000 and operating cash flow of MYR 14,903,000 suggest a stable financial position. The company's capital expenditure of MYR -15,883,000 indicates that it is investing in its operations, which could support future growth. However, the company's free cash flow of MYR 200,000 is relatively low, which may limit its ability to reinvest in the business. The risk assessment for PMCK Bhd indicates a medium liquidity risk and a low dilution risk. The company's key flags include a negative net cash position after subtracting total debt, which could affect its liquidity. The company's dilution risk is low, suggesting that there is little immediate threat to shareholder value from new share issuances. Recent events related to PMCK Bhd are not specified in the provided data. However, the company's financial performance and risk profile suggest that it is a stable player in the healthcare sector. The company's operations and financial metrics indicate that it is well-positioned to continue providing its services and maintaining its market position.
Key takeaways
  • PMCK Bhd has a strong capital structure with a low debt-to-equity ratio of 0.24.
  • The company's return on equity of 12.53% and return on assets of 9.24% indicate a healthy profitability.
  • PMCK Bhd's revenue is concentrated in its three main segments: Specialist consultant services, Healthcare support services, and Other services.
  • The company's liquidity is assessed as medium, with a current ratio of 2.84.
  • PMCK Bhd has a negative net cash position after subtracting total debt, which could pose a liquidity risk.
  • The company's dilution risk is low, suggesting that there is little immediate threat to shareholder value from new share issuances.
  • # RATIONALES
  • {
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$93.3M
Gross profit$29.0M
Operating income$16.1M
Net income$11.3M
R&D
SG&A
D&A
SBC
Operating cash flow$14.9M
CapEx-$15.9M
Free cash flow$200.0k
Total assets$122.7M
Total liabilities$32.2M
Total equity$90.5M
Cash & equivalents
Long-term debt$22.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$90.5M
Net cash-$22.1M
Current ratio2.8
Debt/Equity0.2
ROA9.2%
ROE12.5%
Cash conversion1.3%
CapEx/Revenue-17.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricPMCKActivity
Op margin17.3%11.5% medp25 9.9% · p75 15.0%top quartile
Net margin12.2%8.6% medp25 6.3% · p75 12.4%above median
Gross margin31.1%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-17.0%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity24.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 03:09 UTC#16b75c91
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 03:11 UTCJob: 21737fc4